Metformin attenuates developmental myelination
- 1Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY 11794 USA
Abstract
Background: Developmental myelination is a protracted process spanning almost three decades. Many regions of the brain undergo developmental myelination throughout childhood and adolescence. Cognitive, motor, and behavioral performance rely on precise spatiotemporal development of myelin. Metformin, an FDA-approved treatment for Type II Diabetes Mellitus, can play a neuroprotective role in adult and aged rodent models of myelin loss by increasing oligodendrocyte production, modulating neuroinflammation, and accelerating myelin repair. However, metformin’s ability to influence developmental myelination remains largely unknown, in spite of its approval for use in children aged 10 years and older.
Methods: In this study we investigated the ability of metformin to impact developmental myelination by delivering it either during myelination onset, or during a period of rapid myelination. In addition, we delivered metformin to isolated primary oligodendrocyte progenitor cells and newly-formed oligodendrocytes, and studied oligodendrocyte differentiation and myelin membrane outgrowth.
Results: We found that metformin treatment attenuated myelination in anterior white matter regions in juvenile mice compared to control littermates, despite leaving oligodendrocyte densities unchanged. Analysis of myelin ultrastructure further revealed that metformin treatment led to fewer axons being myelinated and an increase in aberrant myelin structures. Using primary oligodendrocyte cultures, we found that newly-differentiated oligodendrocytes treated with metformin developed myelin sheets that were ~ 50% smaller compared to controls, without affecting the total number of Olig2 + or MBP+ oligodendrocytes.
Conclusions: These results suggest that during development, metformin restricts the myelinogenic capacity of individual oligodendrocytes but does not influence oligodendrocyte production. These findings have implications for the clinical use of metformin in young patients in which myelination is ongoing.
Graphical Abstract:
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12967-026-08757-z.
Related
- Developmental prefrontal myelination shapes inhibitory interneuron function and adult social behavior
- Hippocampal subfield macrostructure and myelination demonstrate distinct maturational signatures
- Shift in phospholipid and fatty acid contents accompanies brain myelination
- Multi-parametric ex vivo magnetic resonance imaging for myelination in the developing mouse brain
- Loss of polr1c disrupts myelination in a zebrafish model of POLR1C-associated disease
BibTeX
@article{azmi2026metformin,
title = {{Metformin attenuates developmental myelination}},
author = {M. A. Azmi and A. Candia Flores and H. Colognato},
journal = {Journal of Translational Medicine},
year = {2026},
month = aug,
doi = {10.1186/s12967-026-08757-z},
url = {https://doi.org/10.1186/s12967-026-08757-z},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Metformin attenuates developmental myelination
AU - M. A. Azmi
AU - A. Candia Flores
AU - H. Colognato
PY - 2026
DA - 2026/08/06
JO - Journal of Translational Medicine
DO - 10.1186/s12967-026-08757-z
UR - https://doi.org/10.1186/s12967-026-08757-z
AB - Background: Developmental myelination is a protracted process spanning almost three decades. Many regions of the brain undergo developmental myelination throughout childhood and adolescence. Cognitive, motor, and behavioral performance rely on precise spatiotemporal development of myelin. Metformin, an FDA-approved treatment for Type II Diabetes Mellitus, can play a neuroprotective role in adult and aged rodent models of myelin loss by increasing oligodendrocyte production, modulating neuroinflammation, and accelerating myelin repair. However, metformin’s ability to influence developmental myelination remains largely unknown, in spite of its approval for use in children aged 10 years and older. Methods: In this study we investigated the ability of metformin to impact developmental myelination by delivering it either during myelination onset, or during a period of rapid myelination. In addition, we delivered metformin to isolated primary oligodendrocyte progenitor cells and newly-formed oligodendrocytes, and studied oligodendrocyte differentiation and myelin membrane outgrowth. Results: We found that metformin treatment attenuated myelination in anterior white matter regions in juvenile mice compared to control littermates, despite leaving oligodendrocyte densities unchanged. Analysis of myelin ultrastructure further revealed that metformin treatment led to fewer axons being myelinated and an increase in aberrant myelin structures. Using primary oligodendrocyte cultures, we found that newly-differentiated oligodendrocytes treated with metformin developed myelin sheets that were ~ 50% smaller compared to controls, without affecting the total number of Olig2 + or MBP+ oligodendrocytes. Conclusions: These results suggest that during development, metformin restricts the myelinogenic capacity of individual oligodendrocytes but does not influence oligodendrocyte production. These findings have implications for the clinical use of metformin in young patients in which myelination is ongoing. Graphical Abstract: Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12967-026-08757-z.
SN - 1479-5876
ER -